Table 1 Demographic and clinical characteristics of different study groups
Characteristics | Healthy Donors n = 94 | Non-severe COVID-19 n = 80 | Severe COVID-19 n = 19 | Severe influenza A n = 37 |
|---|---|---|---|---|
Age groups (years), median (IQR) | 47 (36, 68) | 37 (30, 49) | 67 (53, 74) | 67 (54,84) |
Gender N, (%) | ||||
Male | 44 (47.0) | 41 (51.0) | 15 (79.0) | 28 (76.0) |
Female | 50 (53.0) | 39 (49.0) | 4 (21.0) | 9 (24.0) |
Admission time, median (IQR) | / | 4 (2, 7) | 5 (4.5, 10) | 3 (2, 5) |
Common Symptoms N,(%) | ||||
Fever | / | 58 (73.0) | 19 (100.0) | 37 (100.0) |
Cough | / | 38 (48.0) | 19 (100.0) | 37 (100.0) |
Dyspnea | / | 0 | 19 (100.0) | 28 (76.0) |
Co-existing complications N,(%) | ||||
Other | / | 19 (24.0) | 12 (63.0) | 33 (89.0) |
Hypertension | / | 16 (20.0) | 8 (42.0) | 23 (62.0) |
Diabetes | / | 4 (5.0) | 4 (21.0) | 9 (24.0) |
COPD | / | 1 (1.0) | 1 (5.0) | 7 (19.0) |
Cardiovascular disease | / | 0 | 2 (11.0) | 13 (35.0) |
Renal disease | / | 0 | 1 (5.0) | 2 (5.0) |
Autoimmune disorders | / | 2 (3.0) | 3 (16.0) | 0 (0) |
Outcome N,(%) | ||||
Survival | / | 80 (100.0) | 18 (95.0) | 33 (89.0) |
Deaths | / | 0 | 1 (5.0) | 4 (11.0) |